000120072 001__ 120072
000120072 005__ 20240228135010.0
000120072 0247_ $$2doi$$a10.18632/oncotarget.2611
000120072 0247_ $$2pmid$$apmid:25361003
000120072 0247_ $$2pmc$$apmc:PMC4294349
000120072 0247_ $$2altmetric$$aaltmetric:2843246
000120072 037__ $$aDKFZ-2017-00659
000120072 041__ $$aeng
000120072 082__ $$a610
000120072 1001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b0$$eFirst author$$udkfz
000120072 245__ $$aNeuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells.
000120072 260__ $$a[S.l.]$$bImpact Journals LLC$$c2014
000120072 3367_ $$2DRIVER$$aarticle
000120072 3367_ $$2DataCite$$aOutput Types/Journal article
000120072 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1490785804_9407
000120072 3367_ $$2BibTeX$$aARTICLE
000120072 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120072 3367_ $$00$$2EndNote$$aJournal Article
000120072 520__ $$aIn neuroblastoma, the most common solid tumor of childhood, excellent prognosis is associated with extensive Schwann cell (SC) content and high-level expression of the neurotrophin receptor, NTRK1/TrkA, which is known to mediate neuroblastoma cell differentiation. We hypothesized that both stromal composition and neuroblastic differentiation are based on bidirectional neuroblastoma-SC interaction. Reanalysis of microarray data from human SY5Y neuroblastoma cells stably transfected with either NTRK1 or NTRK2 revealed upregulation of the mRNA for the SC growth factor, NRG1, in NTRK1-positive cells. Media conditioned by NTRK1-expressing neuroblastoma cells induced SC proliferation and migration, while antibody-based NRG1 neutralization significantly decreased these effects. Vice versa, NRG1-stimulated SC secreted the NTRK1-specific ligand, NGF. SC-conditioned medium activated the NTRK1 receptor in a neuroblastoma cell culture model conditionally expressing NTRK1 and induced differentiation markers in NTRK1-expressing cells. NTRK1 induction in neuroblastoma xenografts mixed with primary SC also significantly reduced tumor growth in vivo. We propose a model for NTRK1-mediated and NRG1-dependent attraction of adjacent SC, which in turn induce neuroblastic differentiation by secretion of the NTRK1-specific ligand, NGF. These findings have implications for understanding the mature and less malignant neuroblastoma phenotype associated with NTRK1 expression, and could assist the development of new therapeutic strategies for neuroblastoma differentiation.
000120072 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000120072 588__ $$aDataset connected to CrossRef, PubMed,
000120072 650_7 $$2NLM Chemicals$$aMembrane Glycoproteins
000120072 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$aProtein-Tyrosine Kinases
000120072 650_7 $$0EC 2.7.10.1$$2NLM Chemicals$$atropomyosin-related kinase-B, human
000120072 7001_ $$aMahlow, Ellen$$b1
000120072 7001_ $$aOdersky, Andrea$$b2
000120072 7001_ $$aLindner, Sven$$b3
000120072 7001_ $$aStephan, Harald$$b4
000120072 7001_ $$aBendix, Ivo$$b5
000120072 7001_ $$aEggert, Angelika$$b6
000120072 7001_ $$aSchramm, Alexander$$b7
000120072 7001_ $$0P:(DE-He78)91317a47fc8532e3daf0d0b362c2a27e$$aSchulte, Johannes$$b8$$eLast author$$udkfz
000120072 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.2611$$gVol. 5, no. 22, p. 11180 - 11192$$n22$$p11180 - 11192$$tOncoTarget$$v5$$x1949-2553$$y2014
000120072 909CO $$ooai:inrepo02.dkfz.de:120072$$pVDB
000120072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000120072 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91317a47fc8532e3daf0d0b362c2a27e$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000120072 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000120072 9141_ $$y2014
000120072 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000120072 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120072 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120072 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120072 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120072 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120072 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120072 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000120072 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000120072 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000120072 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x1
000120072 980__ $$ajournal
000120072 980__ $$aVDB
000120072 980__ $$aI:(DE-He78)B062-20160331
000120072 980__ $$aI:(DE-He78)L401-20160331
000120072 980__ $$aUNRESTRICTED